Clinical Trial Update: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating exemestane with or without entinostat in recurrent hormone receptor-positive, HER2-negative breast cancer that is locally advanced or m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• Entinostat (entinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-11-16